ANTX- AN2 Therapeutics, Inc.

Trade Summary

1 week ago, Readnour Robin Shane, serving as Dir at AN2 Therapeutics, Inc. (ANTX), sold 16,119 shares at $6.04 per share, for a total transaction value of $97,323.13. Following this transaction, Readnour Robin Shane now holds 625,350 shares of ANTX.

This sale represents a 2.51% decrease in Readnour Robin Shane's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, September 3, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, September 8, 2026 at 7:42 PM ET, 5 days after the trade was made.

AN2 Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.